Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F25%3AN0000021" target="_blank" >RIV/00023728:_____/25:N0000021 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10498472

Výsledek na webu

<a href="https://doi.org/10.1093/rheumatology/keaf229" target="_blank" >https://doi.org/10.1093/rheumatology/keaf229</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/rheumatology/keaf229" target="_blank" >10.1093/rheumatology/keaf229</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project.

Popis výsledku v původním jazyce

The lack of uniform terminology and abbreviations for anti-synthetase syndrome has led to significant challenges in research and clinical practice. This study aimed to establish an international consensus on a standardized nomenclature and abbreviation among a diverse group of global myositis experts and patient representatives. This qualitative project was approved by the International Myositis Assessment and Clinical Studies Group (IMACS). Based on the outcomes of a literature review and preliminary survey, list of terms for nomenclature and abbreviations was finalized. Subsequently, two rounds of the Delphi survey were conducted among myositis experts and patient participants to ascertain current practices and preferences. Using Nominal Group Technique (NGT), the project steering committee developed a consensus nomenclature and abbreviation. A total of 241 and 132 myositis experts from six continents, 35 countries and 9 specialities participated in round 1 and round 2 of the Delphi survey, respectively. The results indicated a preference for the terms anti-synthetase syndrome, antisynthetase syndrome and anti-tRNA synthetase syndrome. The abbreviations ASS, ASyS and ASSD were most used, though ASS received notable disapproval. The steering committee, including twenty-five myositis experts and three patient representatives from diverse backgrounds and geographical locations, reached a consensus on 'anti-synthetase syndrome' as the preferred nomenclature and ASyS as the preferred abbreviation, with 100% and 93.1% votes, respectively. The terms anti-synthetase syndrome and ASyS should be adopted as the standard nomenclature and abbreviation in both research and clinical practice. This standardization is expected to increase consistency within the literature.

Název v anglickém jazyce

Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project.

Popis výsledku anglicky

The lack of uniform terminology and abbreviations for anti-synthetase syndrome has led to significant challenges in research and clinical practice. This study aimed to establish an international consensus on a standardized nomenclature and abbreviation among a diverse group of global myositis experts and patient representatives. This qualitative project was approved by the International Myositis Assessment and Clinical Studies Group (IMACS). Based on the outcomes of a literature review and preliminary survey, list of terms for nomenclature and abbreviations was finalized. Subsequently, two rounds of the Delphi survey were conducted among myositis experts and patient participants to ascertain current practices and preferences. Using Nominal Group Technique (NGT), the project steering committee developed a consensus nomenclature and abbreviation. A total of 241 and 132 myositis experts from six continents, 35 countries and 9 specialities participated in round 1 and round 2 of the Delphi survey, respectively. The results indicated a preference for the terms anti-synthetase syndrome, antisynthetase syndrome and anti-tRNA synthetase syndrome. The abbreviations ASS, ASyS and ASSD were most used, though ASS received notable disapproval. The steering committee, including twenty-five myositis experts and three patient representatives from diverse backgrounds and geographical locations, reached a consensus on 'anti-synthetase syndrome' as the preferred nomenclature and ASyS as the preferred abbreviation, with 100% and 93.1% votes, respectively. The terms anti-synthetase syndrome and ASyS should be adopted as the standard nomenclature and abbreviation in both research and clinical practice. This standardization is expected to increase consistency within the literature.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

RHEUMATOLOGY

ISSN

1462-0324

e-ISSN

1462-0332

Svazek periodika

64

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

4930-4936

Kód UT WoS článku

001488427400001

EID výsledku v databázi Scopus

2-s2.0-105015353190